"Yttrium Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
| Descriptor ID |
D015021
|
| MeSH Number(s) |
D01.268.558.975.500.800 D01.268.956.890.500.800 D01.496.749.960 D01.496.943.800 D01.552.550.975.500.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Yttrium Radioisotopes".
Below are MeSH descriptors whose meaning is more specific than "Yttrium Radioisotopes".
This graph shows the total number of publications written about "Yttrium Radioisotopes" by people in this website by year, and whether "Yttrium Radioisotopes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Yttrium Radioisotopes" by people in Profiles.
-
Combination Ipsilateral Lobar and Segmental Radioembolization Using Glass Yttrium-90 Microspheres for Treatment of Multifocal Hepatic Malignancies. J Vasc Interv Radiol. 2018 08; 29(8):1110-1116.
-
Assessing Intra-arterial Complications of Planning and Treatment Angiograms for Y-90 Radioembolization. Cardiovasc Intervent Radiol. 2017 May; 40(5):704-711.
-
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
-
Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998 Nov; 4(11):2691-700.
-
Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol. 1993 Apr; 11(4):698-703.